Press Room - Sanofi US News

Media Room Menu

Aug 6, 2019

Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis

U.S. FDA submission for children planned for 4Q 2019
Jul 29, 2019

Sanofi delivered solid growth in Q2 2019
- Photos 4
Jul 10, 2019

FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma
Jun 26, 2019

FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis

* First biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP)
May 15, 2019

Sanofi oncology pipeline targeting various cancers highlighted at ASCO 2019

- Pivotal Phase 3 data evaluated isatuximab (anti-CD38) in combination with pomalidomide/dexamethasone in prolonging progression-free survival in relapsed/refractory multiple myeloma

Show per page